Proton magnetic resonance spectroscopy measures related to short-term symptomatic outcome in chronic schizophrenia.

Neuroscience letters

Volumn 547, Issue , 2013, Pages 37-41

  Szulc, Agata ^a   Konarzewska, Beata ^b   Galinska Skok, Beata ^b   Lazarczyk, Joanna ^b   Waszkiewicz, Napoleon ^b   Tarasow, Eugeniusz ^b   Milewski, Robert ^b   Walecki, Jerzy ^b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; PROTON;

ADULT; BRAIN; DRUG RESISTANCE; FEMALE; HUMAN; MALE; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PHYSIOLOGY; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; DRUG RESISTANCE; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROTONS; SCHIZOPHRENIA;

EID: 84892391386     PISSN: None     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.04.051     Document Type: Article

References (35)

1. R. Bartha P.C. Williamson D.J. Drost A. Malla T.J. Carr L. Cortese G. Canaran R.J. Rylett R.W. Neufeld Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy Arch. Gen. Psychiatry 54 1997 959 965
2. S. Bazire Psychotropic Drug Directory 2003/04: The Professional's Pocket Handbook and Aide Memoire 2003 Fivepin Salisbury
3. S. Brugger J.M. Davis S. Leucht J.M. Stone Proton magnetic resonance spectroscopy and illness stage in schizophrenia – a systematic review and meta-analysis Biol. Psychiatry 69 2011 495 503
4. C.U. Correll A.K. Malhotra S. Kaushik M. McMeniman J.M. Kane Early prediction of antipsychotic response in schizophrenia Am. J. Psychiatry 160 2003 2063 2065
5. A. Egerton S. Brugger M. Raffin G.J. Barker D.J. Lythgoe P.K. McGuire J.M. Stone Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia Neuropsychopharmacology 2012
6. R. Emsley P.P. Oosthuizen M. Kidd L. Koen D.J. Niehaus H.J. Turner Remission in first-episode psychosis: predictor variables and symptom improvement patterns J. Clin. Psychiatry 67 2006 1707 1712
7. M.B. First Structured Clinical Interview for DSM-IV Axis I Disorders: SCID – I: Clinician Version: Administration Booklet 1997 American Psychiatric Press Washington, DC
8. P. Fusar-Poli I. Bonoldi A.R. Yung S. Borgwardt M.J. Kempton L. Valmaggia F. Barale E. Caverzasi P. McGuire Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk Arch. Gen. Psychiatry 69 2012 220 229
9. P. Fusar-Poli J. Radua P. McGuire S. Borgwardt Neuroanatomical maps of psychosis onset: voxel-wise meta-analysis of antipsychotic-naive VBM studies Schizophr. Bull. 38 2012 1297 1307
10. 1H MRS) findings in first-episode schizophrenia Med. Sci. Monit. 15 2009 CR82 CR88
11. W. Guy ECDEU Assessment Manual for Psychopathology 1976 DHEW Publ ADM-76-338 534 537
12. T. Kasparek R. Prikryl D. Schwarz H. Kucerova R. Marecek M. Mikl J. Vanicek E. Ceskova Gray matter morphology and the level of functioning in one-year follow-up of first-episode schizophrenia patients Prog. Neuropsychopharmacol. Biol. Psychiatry 33 2009 1438 1446
13. S.R. Kay A. Fiszbein L.A. Opler The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr. Bull. 13 1987 261 276
14. S.Y. Kim H. Lee H.J. Kim E. Bang S.H. Lee D.W. Lee D.C. Woo C.B. Choi K.S. Hong C. Lee B.Y. Choe In vivo and ex vivo evidence for ketamine-induced hyperglutamatergic activity in the cerebral cortex of the rat: potential relevance to schizophrenia NMR Biomed. 24 2011 1235 1242
15. 1H MRS studies Schizophr. Bull. 39 2013 120 129
16. T. Ohnuma T. Suzuki H. Arai Hypothesis: minimal changes in neural transmission in schizophrenia: decreased glutamatergic and GABAergic functions in the prefrontal cortex Prog. Neuropsychopharmacol. Biol. Psychiatry 29 2005 889 894
17. P. Ohrmann A. Siegmund T. Suslow K. Spitzberg A. Kersting V. Arolt W. Heindel B. Pfleiderer Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study Schizophr. Res. 73 2005 153 157
18. X. Peng H. Ascher-Svanum D.E. Faries V.L. Stauffer S. Kollack-Walker B.J. Kinon J.M. Kane Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy ClinicoEcon. Outcomes Res. 3 2011 79 87
19. J. Radua S. Borgwardt A. Crescini D. Mataix-Cols A. Meyer-Lindenberg P.K. McGuire P. Fusar-Poli Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication Neurosci. Biobehav. Rev. 36 2012 2325 2333
20. A.J. Ross P.S. Sachdev Magnetic resonance spectroscopy in cognitive research Brain Res. Brain Res. Rev. 44 2004 83 102
21. L.M. Rowland J.R. Bustillo P.G. Mullins R.E. Jung R. Lenroot E. Landgraf R. Barrow R. Yeo J. Lauriello W.M. Brooks Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study Am. J. Psychiatry 162 2005 394 396
22. R. Schennach-Wolff S. Meyer F. Seemuller M. Jager M. Schmauss G. Laux H. Pfeiffer D. Naber L.G. Schmidt W. Gaebel J. Klosterkotter I. Heuser W. Maier M.R. Lemke E. Ruther S. Klingberg M. Gastpar H.J. Moller M. Riedel Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder J. Psychiatr. Res. 45 2011 1639 1647
23. R. Schennach-Wolff F.H. Seemuller A. Mayr W. Maier S. Klingberg I. Heuser J. Klosterkotter M. Gastpar H. Hafner H. Sauer F. Schneider W. Gaebel M. Jager H.J. Moller M. Riedel An early improvement threshold to predict response and remission in first-episode schizophrenia Br. J. Psychiatry 196 2010 460 466
24. 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis Neuropsychopharmacology 30 2005 1949 1962
25. J.R. Strawn N.C. Patel W.J. Chu J.H. Lee C.M. Adler M.J. Kim H.S. Bryan D.C. Alfieri J.A. Welge T.J. Blom J.J. Nandagopal S.M. Strakowski M.P. DelBello Glutamatergic effects of divalproex in adolescents with mania: a proton magnetic resonance spectroscopy study J. Am. Acad. Child Adolesc. Psychiatry 51 2012 642 651
26. A. Szulc B. Galinska-Skok N. Waszkiewicz D. Bibulowicz B. Konarzewska E. Tarasow Proton magnetic resonance spectroscopy changes after antipsychotic treatment Curr. Med. Chem. 20 2013 414 427
27. A. Szulc B. Galinska E. Tarasow N. Waszkiewicz B. Konarzewska R. Poplawska D. Bibulowicz K. Simonienko J. Walecki Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment Pharmacopsychiatry 44 2011 148 157
28. 1H MRS) study Pol. J. Radiol. 69 2004 33 36
29. J. Theberge Y. Al-Semaan P.C. Williamson R.S. Menon R.W. Neufeld N. Rajakumar B. Schaefer M. Densmore D.J. Drost Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS Am. J. Psychiatry 160 2003 2231 2233
30. J. Theberge R. Bartha D.J. Drost R.S. Menon A. Malla J. Takhar R.W. Neufeld J. Rogers W. Pavlosky B. Schaefer M. Densmore Y. Al-Semaan P.C. Williamson Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers Am. J. Psychiatry 159 2002 1944 1946
31. J. Theberge K.E. Williamson N. Aoyama D.J. Drost R. Manchanda A.K. Malla S. Northcott R.S. Menon R.W. Neufeld N. Rajakumar W. Pavlosky M. Densmore B. Schaefer P.C. Williamson Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia Br. J. Psychiatry 191 2007 325 334
32. P. Tibbo C. Hanstock A. Valiakalayil P. Allen 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia Am. J. Psychiatry 161 2004 1116 1118
33. N.M. van Veelen M. Vink N.F. Ramsey M. van Buuren J.M. Hoogendam R.S. Kahn Prefrontal lobe dysfunction predicts treatment response in medication-naive first-episode schizophrenia Schizophr. Res. 129 2011 156 162
34. S.J. Wood G.E. Berger M. Lambert P. Conus D. Velakoulis G.W. Stuart P. Desmond P.D. McGorry C. Pantelis Prediction of functional outcome 18 months after a first psychotic episode: a proton magnetic resonance spectroscopy study Arch. Gen. Psychiatry 63 2006 969 976
35. S.W. Woods Chlorpromazine equivalent doses for the newer atypical antipsychotics J. Clin. Psychiatry 64 2003 663 667